cyrilzakka/clinical-trials huggingface dataset:
Opinions of Company Representatives About Neuromodulation

The goal of this online survey is to gain further insight in the goals, expectations and definition of success for neuromodulation for pain, according to neuromodulation company representatives.


Eligibility Criteria:
Inclusion Criteria:

- Male and female adults who are involved in the management of chronic pain and more specifically in neuromodulation for pain as company representatives will be eligible to complete the survey.

Exclusion Criteria:

- Not a company representative.
Feasibility Evaluation - Blood Glucose Level Monitoring by Microwave Metamaterial Sensor in Blood Samples.

The goal of this clinical trial is to test microwave metamaterial glucose sensor on blood samples. It means to compare the results of glucose values obtained by microwave metamaterial sensor and by standard biochemical analyzer.

Participants will include physiological and pathological populations. Participants donate approximately 5 ml of blood sample. Three sample tubes will be collected from ten adult participants. In the first test tube, the blood glucose content will be determined by a validated biochemical analyzer (Roche, Switzerland). In the remaining volume of the blood sample, the dielectric parameters (relative permittivity and conductivity) will be estimated using a coaxial probe (Keysight, USA). Microwave metamaterial sensors with 5, 7 and 9 unit cells will be loaded with blood samples and the specific scattering matrices will be obtained using a vector network analyzer. The main monitored outcome measure will be the phase of parameter S21.

Eligibility Criteria:
Inclusion Criteria:

* blood glucose can be measured with standard biochemical analyzer

Exclusion Criteria:

* minimum age limit 18 years
Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma

A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy plus Bevacizumab followed by consolidation therapy with Ipilimumab (BBI).

A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy (Temodar,Cisplatin, Velban,IL2 and IFN)plus Bevacizumab followed by consolidation therapy with Ipilimumab (BBI)

Eligibility Criteria:
Inclusion Criteria:

1. Stage 4 or unresectable stage 3 metastatic melanoma with or without measurable disease
2. Age 18-70 years old
3. Adequate pulmonary and cardiac function for high-dose IL-2
4. PS 0-2
5. Previous ipilimumab therapy will not exclude patients, but patients with previous ipilimumab will have separate efficacy analysis

Exclusion Criteria:

1. Brain metastases
2. Creatinine \> 2x ULN; bilirubin \> 3, WBC \< 3500, Platelets \< 100,000, Hgb \< 9
3. Another active malignancy
4. Gastrointestinal tract metastases except rectal metastases or primary are allowable
5. Previous therapy for metastatic disease with chemotherapy of duration over 3 months or with high-dose interleukin-2
6. History of colitis or autoimmune disease such as lupus or rheumatoid arthritis
7. Bevacizumab-related contraindications: Hemoptysis or history of severe bleeding, uncontrolled hypertension, proteinuria with protein/creatinine ratio \> 1, acute myocardial infarction within 6 months
The Anti-fungal Effect of Miconazol Versus Miconazol-Loaded Chitosan Nanoparticles

Objective: this study aimed to evaluate the therapeutic effects of topical application of miconazole and miconazole-loaded chitosan nanoparticles in treatment diabetic patients with oral candidiasis.

Abstract:

Objective: this study aimed to evaluate the therapeutic effects of topical application of miconazole and miconazole-loaded chitosan nanoparticles in treatment diabetic patients with oral candidiasis.

Subjective and methods:

In this randomized controlled clinical trial,. A total of 80 diabetic patients presenting with symptomatic oral candidiasis were randomly assigned into two treatment groups: miconazole and miconazole-loaded chitosan nanoparticles. The patients were treated for a duration 28days , and clinical assessments were conducted at baseline, 7, 14, 21 and 28 days.

Microbiological analysis was performed to determine the Candida species and assess their susceptibility to the antifungal agents. Clinical parameters, including signs and symptoms of oral candidiasis, were also evaluated.

.

Eligibility Criteria:
Inclusion Criteria:

1. uncontrolled diabetes patients with oral candidiasis and their uncontrolled diabetes were confirmed by doing glycated hemoglobin test and their range is \>7.0%,
2. age ranged from 30-65 years
3. patients were willing to participate in this study

Exclusion Criteria:

1. immunocompromised and patients with systemic diseases that can cause muscle weakness as Parkinson's disease, or others that can limit their cognitive functioning such as dementia
2. pregnant
3. nursing women
4. smokers
5. alcoholic patients were also excluded from the study.
6. should not have a history of use of any drugs that can cause hyposalivation or broad spectrum antibiotics, within the last month.
Corneal Topography Asymmetry Indices Changes After Corneal Refractive Surgery

To evaluate the changes that occur in the corneal indices after corneal refractive surgery either PRK or LASIK.

Retrospectively review the medical records of all patients who underwent refractive surgery referred from the out-patient clinic of Tanta University hospital between September 2015 and September 2020 .

Data collection will include:

Preoperative and postoperative Evaluation: Age, sex, uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest and cycloplegic refraction, Slit lamp biomicroscopy, fundus examination.

Data of Corneal Tomography keratometric using Scheimpflug camera (Pentacam Oculus- Germany) :that includes the following indices

1. Average keratometric value (K mean) in diopters
2. Maximum simulated keratometry (Kmax) in diopters
3. Index of Surface Variance (ISV) in microns
4. Index of Vertical Asymmetey (IVA) in microns
5. Radii Minimum (R min) in microns
6. Index of height asymmetry (IHA) in microns
7. Index of height decantation (IHD) in microns
8. Aberration coefficient (ABR)

The data of the pentacam will be collected pre-operative and analyzed at 1 month, 3 months and 6 months with recording of the complications.

Eligibility Criteria:
Inclusion Criteria:

* Patients who underwent refractive surgery either PRK, LASIK with age between 19 and 35 years old

Exclusion Criteria:

* Kertoconus.

  * Corneal scarring.
  * Previous corneal infections.
  * Minimum corneal thickness at the thinnest location less than 400 µm.
  * History of uveitis or ocular allergy.
  * Pre-existing glaucoma.
  * Data not available
Respiratory and Pelvic Floor Muscle Functions of Children With Lower Urinary Tract Dysfunction

Lower urinary tract dysfunctions (LUTD) are disorders that can occur in the storage and voiding stages of bladder function other than neurological disease or lower urinary tract obstruction. Storage symptoms are increased or decreased voiding frequency, urinary incontinence, urgency and nocturia, while voiding symptoms are classified as hesitation, straining, weak stream and intermittent voiding. Other symptoms are holding maneuvers, feeling of incomplete voiding, post-voiding dripping, genital and lower urinary tract pain. Epidemiological studies show that the prevalence of LUTD is high in school-aged children, with rates as high as 22%. Very little is known about pelvic floor muscle training in children. Relaxation in the pelvic floor muscles is very important for the continuity of micturition and defecation functions. Respiratory function is one of the key elements in the relaxation of the pelvic floor. The relationship of the pelvic floor muscles with the diaphragm and their role in intra-abdominal pressure regulation have been demonstrated by many studies. In the adult population, it has been emphasized that the respiratory pattern should be corrected in pelvic floor dysfunctions and pelvic floor muscle training should be provided in those with respiratory problems. In the literature, rehabilitation programs for children with LUTD are treatment approaches in which respiratory and pelvic floor muscle training are applied together, but it has not been clearly stated which isolated approach is responsible for the resulting effect. In addition, these studies have emphasized that diaphragmatic exercises reduce or improve symptoms through the relaxation mechanism they create in the abdominal wall. However, unlike the literature, one of the aims of this study is to reveal the relationship between inspiratory and expiratory muscle strength and LUTD.


Eligibility Criteria:
Inclusion Criteria in LUTD group:

* Diagnosed with LUTD,
* Nighttime enuresis at least twice a week for at least 3 consecutive months.
* Daytime enuresis at least once a month for at least 3 consecutive months.
* Girls aged 6-14,
* who consent to participate in the study with the consent of their mother and father or legal guardian (legal representative) will be included in the study.

Inclusion Criteria for healthy individuals in the study:

* Girls aged 6-14,
* who consent to participate in the study with the consent of their mother and father or legal guardian (legal representative) will be included in the study.

Exclusion Criteria:

* Children under 6 years of age,
* Anatomical changes in the urinary system,
* Spina bifida,
* History of active urinary tract infection,
* Neurological disease,
* An accompanying respiratory system disease (asthma and a history of frequent upper respiratory tract infections),
* Cognitive impairment,
* Mental retardation,
* Chronic kidney disease,
* Who have previously undergone orthopedic surgery will not be included in the study.
Carbohydrate Loading in Type 2 Diabetes Mellitus

The goal of this clinical trial is to learn the effects of preoperative carbohydrate loading on perioperative blood glucose levels and insulin resistance in type 2 diabetes mellitus undergo elective surgery. The main questions it aims to answer are:

* Does carbohydrate loading affects perioperative blood glucose and insulin resistance in type 2 diabetes mellitus patients undergo surgery?
* How are the incident of perioperative hyperglycemia and hypoglycemia between subjects who receive placebo compared with subjects who receive carbohydrate loading
* How are the hyperglycemia-related complications comparison between two groups?

Researchers will compare the carbohydrate loading intervention to placebo (regular drinking water with zero-calorie sweetener) to see the effects of carbohydrate loading to blood glucose levels and insulin resistance (by HOMA-IR value)

Participants will:

* randomized to carbohydrate loading (CHO) group or placebo
* checked for preoperative, intraoperative, postoperative blood glucose, and preoperative and postoperative insulin level
* evaluated for any hyperglycaemia-related complications


Eligibility Criteria:
Inclusion Criteria:

* Controlled type 2 diabetes mellitus with any treatment
* BMI \<30 kg/m2
* Non-major elective surgery

Exclusion Criteria:

* Subject refusal
* Geriatric patients with frailty score \>4
* Subjects with critical illness
* Subjects received steroid treatment
* Subjects received total parenteral nutrition
* Subjects with intestinal obstruction
* Subjects with impaired liver function
Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis

The purpose of this retrospective study is to evaluate the effectiveness of CPM nasal spray as part of the treatment of COVID-19 and its impact on clinical symptoms. Two cohort groups will be compared (CPM vs. standard care). The hypothesis to be tested is that patients treated with CPM nasal spray showed more rapid clinical improvement than those treated with standard of care alone. Clinical improvement will be evaluated by the total number of days with the manifestation of COVID-19 symptoms, including cough, nasal congestion, ageusia, and anosmia, among others. The rate of hospitalization between the cohorts will also be evaluated.

The following are categories of interest in patients with COVID-19 treated with ClorNovir:

* Clinical outcomes, as assessed by clinical assessments of clinical symptoms, and incidence of significant clinical events
* Clinical recovery, as assessed by patient-reported outcome measures and clinician-reported outcomes.

The safety objective is to assess the safety and tolerability of ClorNovir.

Eligibility Criteria:
Inclusion Criteria:

* Male or female patients with a documented diagnosis of SAR-CoV-2
* Patients with positive RT-PCR or antigen test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs
* Both vaccinated and unvaccinated (high-risk) persons will be included.
* Willing and able to provide written informed consent (ages greater or equal to 18 years) or parental/guardian consent and patient assent (age \<18 years), as required by the IRB or institution or IRB, per local regulations

Exclusion Criteria:
Using Customized Nasal Conformer in Correction of Cleft Nasal Deformity in Patients with Unilateral Cleft Lip

The goal of the study is to compare the cleft lip repair with and without the usage of customized milled nasal conformers in unilateral cleft lip patients on nostril size , alar cartilage and proportion of symmetry to the normal side .

* Comparing anthropometric measurements similarity between cleft and normal sides such as; nostril width and height , columellar deviation and nasolabial angle.
* Evaluation of degree of similarity using esthetic scales at six months postoperative.

Participants will receive nasal conformers intraoperative with follow up of 6 months.


Eligibility Criteria:
Inclusion Criteria:

1. Patients of both sexes with unilateral cleft lip.
2. Age range 10 - 24 weeks.
3. Hemoglobin more than 10 gm/dl .
4. Weight more than 10 lbs.

Exclusion Criteria:

1. Syndromic patients.
2. Patients with conditions contradicting operation.
3. Patients with Bilateral cleft lip.
4. Patients with previous surgeries in lip and nose.
Dosimetric Comparison of Doses in Both Positions (Prone and Decubitus) for Patient With Breast Cancer

Compare dosimeters in both positions (prone and decubitus) for each patient

Quantitative Physics: dosimetric comparison of doses in target volumes and organs at risk. The technique used is that of which the dose on the organs at risk is as low as possible, and whose dose to the target volume is the closest possible to the prescribed dose (100% of the prescribed dose).

Eligibility Criteria:
Inclusion Criteria:

* Patients with primary breast cancer and in whom conservative post- surgery radiation therapy for breast cancer is prescribed.
* Patients aged over 18 years
* Patients with indication for conservative surgery.
* Resection should be in healthy margin.
* Women of childbearing potential must satisfy a negative pregnancy test at the screening visit and use effective contraception as determined by the physician of the patient throughout the study.

Exclusion Criteria:

* Minor Patient
* Patients whose tumor resection is incomplete
* Patients with an indication of mastectomy
* Patients with a history of radiation therapy of the chest
* Pregnant women, lactating, or of childbearing age without effective contraception.
* Patients who had more than 4 scanners in one year. ( Scanner cervical , thoracic, or abdominal
* Patients with an incompatible condition with monitoring protocol (psychiatric disorder, uncontrolled disease).
* Patient unable to respond to a questionnaire
Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROBAT)

Patients affected by pheochromocytoma (PHEO) have brown-adipose tissue (BAT) hyperactivation. They perform, in routine settings, a FDG PET-CT scan. The high metabolic activity of BAT and its ability to consume both glucose and fatty acid suggest that it may have potential as a therapeutic target in the treatment of obesity. However, alternative non-invasive techniques to PET-CT BAT detection still need more validation. Accordingly, our aim will be to measure the temperature and microcirculation of the skin overlaying BAT depots in the region of FDG-uptake detected by 18F-FDG PET/CT before and after a cold test in PHEO patients.

Objectives and Methodology:

* To analyse the change in temperature and microcirculation of the skin overlaying BAT depots in the region of FDG-uptake detected by 18F-FDG PET/CT before and after a cold test in PHEO patients.
* To check the decreased temperature and microcirculatory response after a cold test following resection of the tumor

All the patients affected by will benefit from a:

* clinical: treatments
* biological evaluations: glycemia, triglycerides, total cholesterol, HDL-C, LDL-C, plasma epinephrine and norepinephrine, urine catecholamine
* cutaneous microcirculation by means of Laser Speckle Imaging will be recorded at rest and during a cold test in the supra-clavicular region
* cutaneous microcirculation by means of Laser Doppler Flowmetry will be recorded at rest and during a cold test with one probe in the supra-clavicular region and one probe in umbilical region
* skin temperature by means of infrared thermography will be recorded at rest and during a cold test in the supra-clavicular region

Patients who will have surgery will be investigated before and after one year following resection of the tumor.

Eligibility Criteria:
Inclusion Criteria:

* Patients with confirmed pheochromocytoma and/or paraganglioma

Exclusion Criteria:

* pregnant woman
* breastfeeding woman
Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII to mitigate experimentally-induced bleeding in healthy volunteers treated with warfarin to reach a targeted INR (International Normalization Ratio).


Eligibility Criteria:
Inclusion Criteria:

* INR below or equal to 1.2

Exclusion Criteria:

* The receipt of any investigational drug within 1 month prior to this trial
* Use of anticoagulation therapy-defined as vitamin K antagonists, platelet antagonists, heparin (or low molecular weight heparin), aspirin or NSAIDs (Non-Steroidal Anti-Inflammatory Drug) within 14 days prior to trial
* African-American race
* Weight above 160 kg
* Supplemental Vitamin K use
Comparing Brain Images Before and After MRI-upgrade - TimFit Upgrade Study

In the Ghent University, an upgrade of the MRI-scanner used for research from Siemens Trio Tim to Siemens Prisma Fit is planned in the near future. As a change of MRI hard- and software might influence brain images, it is necessary to evaluate the images before and after the upgrade.


Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteer

Exclusion Criteria:

* Protheses or artificial implants, no magnetic or metal parts in the body
* Being pregnant or breastfeeding
* Having claustrophobia
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.

The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like a medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.

A Multicenter, Randomized, Double-Blind Parallel Group Placebo-Controlled Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressants in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy

Eligibility Criteria:
Inclusion Criteria:

* Provision of signed and dated informed consent before initiation of any study-related procedures.
* The patient must have a clinical diagnosis of major depressive disorder (MDD) with inadequate response to no more than one antidepressant.
* Outpatient status at enrollment and randomization.

Exclusion Criteria:

* Patients with a lifetime history of bipolar disorder, psychotic disorder or post-traumatic stress disorder.
* Patients with a history of suicide attempts in the past year and/or seen by the investigator as having a significant history of risk of suicide or homicide.
* History of renal insufficiency or impairment or conditions that could affect absorption or metabolism of investigational product.
Home Hospital for Lymphoma

The goal of this research is to evaluate an intervention, which the investigators call "Home Hospital for Lymphoma," that involves remote patient monitoring and home-based supportive care for patients hospitalized with lymphoma at Massachusetts General Hospital.

This research study is a single arm pilot Feasibility Study, which is the first-time investigators are examining this hospital at home intervention for patients with lymphoma.

The research study procedures include screening for eligibility, questionnaires, remote patient monitoring (e.g. patient-reported symptoms and home monitored vital signs) and home-based supportive care (e.g. visits to patients' homes to address and manage any concerning issues identified), and interviews of participants, caregivers, and clinicians asking their perceptions of the Home Hospital for Lymphoma program.

Participants will include 3 groups:

Enrolled participants receiving the hospital at home intervention, caregivers of participants, and clinicians.

Participants will be in the research study for about six months after consent. It is expected that up to 38 participants will take part in this research study.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 or older
* Receiving their lymphoma care with curative intent at MGH (treatment intent based upon chemotherapy order in the electronic medical record)
* Hemodynamically stable during the first 24 hours of hospital admission at MGH
* Residing within the designated geographic area for MGH Home Hospital Service (an approximately 10-mile radius from MGH)
* Able to communicate and respond to questionnaires in English
* Lives with a family member or a friend who supports the patient at home
* Deemed eligible for supportive oncology care at home based on the MGH Home Hospital clinician evaluation

Exclusion Criteria:

* Those admitted to the intensive care unit
* Have high oxygen requirement (FIO2 \> 0.4)
* Experience active angina or cardiac arrythmias
* Have a planned inpatient surgical or interventional procedure
* Have uncontrolled psychiatric illness or impaired cognition that prohibits complying with the study procedures
* Have uncontrolled pain requiring intravenous pain medications
* Those deemed ineligible based on the Home Hospital Service clinician evaluation